about
Targets for therapy in sarcomeric cardiomyopathiesAssessing myocardial perfusion after myocardial infarctionA mutation in the mitochondrial fission gene Dnm1l leads to cardiomyopathyAdenosine stress native T1 mapping in severe aortic stenosis: evidence for a role of the intravascular compartment on myocardial T1 valuesMyocardial perfusion and oxygenation are impaired during stress in severe aortic stenosis and correlate with impaired energetics and subclinical left ventricular dysfunctionA review of the causes of central pontine myelinosis: yet another apoptotic illness?AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes.The role of vascular myoglobin in nitrite-mediated blood vessel relaxationHypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.Hepcidin: the missing link between hemochromatosis and infections.Resistance of Dynamin-related Protein 1 Oligomers to Disassembly Impairs Mitophagy, Resulting in Myocardial Inflammation and Heart FailureFumarate is cardioprotective via activation of the Nrf2 antioxidant pathway.The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension.Natriuretic peptides, respiratory disease, and the right heart.Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigsEffect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.No Evidence of Myocardial Oxygen Deprivation in Nonischemic Heart Failure.Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis.Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.In vivo mouse cardiac hyperpolarized magnetic resonance spectroscopy.Carotid ultrasound imaging: an effective technique for detecting early atherosclerosis-vascular screening for cardiovascular disease has come of age.Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype.Perhexiline.Metabolic mechanisms in heart failure.Impaired energetics in heart failure - a new therapeutic target.The genetics of hypertrophic cardiomyopathy: Teare redux.Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.Genetic cardiomyopathies causing heart failure.Citric acid cycle intermediates in cardioprotection.A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia.Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro.Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systemsDysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism.In vivo alterations in cardiac metabolism and function in the spontaneously hypertensive rat heart.Antimicrobial prophylaxis for endocarditis: emotion or science?Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.Reduced negative surface charge on arterial endothelium explains accelerated atherosclerosis in type 2 diabetic patients.Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosis.
P50
Q27027023-BB70B90C-3CEB-4090-AEB5-84248782A2BCQ27307761-DF43C2FE-2F00-4051-A9CD-9FC5DE4F6D97Q28509163-D74D4FEB-9F53-47FF-B708-E2F012E4DBBAQ30870621-23F61AC5-EB11-423C-9346-CB79FB51D13CQ33562310-E29DB2A4-1A54-4319-89D9-A1561FC512BAQ33953333-68AFE76D-B109-4D7B-82F8-C83C0E67756AQ34211072-F9558825-A864-4625-BE0E-AF056CF5313BQ34530195-2CF641C7-33AE-4164-8D16-653BBA84C00BQ35113389-A4D8313E-0C72-4239-8BD6-0EA89C82D371Q35593166-43A25B56-5E6F-4A0E-9074-B503B0AF1B60Q35775155-ABB5FC16-42B9-490F-BEAC-91EC9CD318C0Q35859412-77B5B0E1-5260-4394-B34C-E435A23A3736Q35888468-E1C80296-92FA-49FC-8444-7EE0C3C55C46Q35919213-525F0199-CB35-43CB-B388-45F2E8AD9D9DQ35954778-3B7B1C7B-1941-4C8A-B398-CEE7F5265AC7Q36266675-040D1BC2-09E7-4965-BEAA-7C19D17AB4D8Q36282692-BC19B010-A11F-4CC4-9366-1DD43D1663C8Q36401243-91E77709-A96C-47CB-AEFF-1CBE627E99A9Q36479365-A26DF35C-3CB0-4392-A72A-967FD152DC84Q36690325-91378167-3237-4B37-B91C-184013817EEEQ36705664-F5D2443E-7399-4F87-8CBE-74F8AE8A96D1Q36774489-315CE04F-188B-4097-871F-BD3F0CE6AA55Q36795930-F4240217-FEB2-4351-B96C-60A1400BB845Q36889876-BBE279CF-8C35-4F93-92DB-565C8BDEC8A7Q37207755-5459CF73-58C1-4E87-A100-7E6BA58165D8Q37226265-0539228E-D06B-4B70-8CC9-C9AB8063BD56Q37893847-9BF59FF3-1A9A-4D03-A98A-F3CEAF3756EDQ38132643-D4C8AA40-1170-4CD0-96F7-4435D19C1DE1Q38291930-9C45E367-5A47-4F20-87A5-192E6C1EBBE6Q39156501-5C787D4F-60D2-4669-AA17-2D8A73E1D1F3Q39446080-A6586FF5-B704-4184-BE23-4E7F784AD25EQ41047339-F4A0E091-D458-4880-8C1A-2E5E99ED5D7DQ41502949-07634B93-8D08-4CBB-8ED5-A3DCF33363D1Q42208253-2A09AD0F-B03E-4BF1-AD09-7BCAE80887BCQ42596900-AF73D957-B7DF-4708-B0EE-E4B98EC1E551Q42714498-0E8E39C7-6887-4641-B28B-9E47C4D32A8CQ42846581-C2DA613C-2195-4617-AD9F-3DDC3EB83FE0Q42870189-869617DD-73E0-4BA8-AACE-3F69B8D5490CQ42957385-3A901869-78DF-40FE-8D62-37AD1EE0E93DQ44816605-E6B3740E-CE7A-4844-A0F0-4F392B5075A1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Houman Ashrafian
@ast
Houman Ashrafian
@en
Houman Ashrafian
@es
Houman Ashrafian
@nl
Houman Ashrafian
@sl
type
label
Houman Ashrafian
@ast
Houman Ashrafian
@en
Houman Ashrafian
@es
Houman Ashrafian
@nl
Houman Ashrafian
@sl
prefLabel
Houman Ashrafian
@ast
Houman Ashrafian
@en
Houman Ashrafian
@es
Houman Ashrafian
@nl
Houman Ashrafian
@sl
P106
P1153
55239206800
P21
P31
P496
0000-0003-3988-378X